News

Business Wire2d
KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has approved EKTERLY® (sebetralstat), a novel ...
Pharmaceutical Technology on MSN1d
FDA approves KalVista’s Ekterly for hereditary angioedema
The US Food and Drug Administration (FDA) has approved KalVista Pharmaceuticals' Ekterly (sebetralstat) as the first and only ...
Elderly flower farmer killed in Maili blaze remembered for warm smile, gentle nature
Maria Pasqual was a flower farmer in Maili, loved by those who encountered her. The family who lives next door to her farm ...
KalVista: FDA Approval Of EKTERLY As Oral On-Demand HAE Drug Is Just Beginning
FDA approval of EKTERLY makes KalVista Pharmaceuticals, Inc. the first to offer an oral on-demand HAE therapy. Click here to find out why KALV is a Strong Buy.
BioPharma Dive1d
After delay, Kalvista wins FDA OK for drug to treat rare swelling disorder
The company had blamed FDA "resource constraints" for the delay, while a rival drug for hereditary angioedema received an ...
MPR18h
FDA Approves Oral Ekterly for On-Demand Hereditary Angioedema Treatment
The Food and Drug Administration (FDA) has approved Ekterly ® (sebetralstat) for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.
Elderly people with dementia being subjected to violence, abuse and neglect in their own homes
There's a clear downside to the Norwegian policy that encourages allowing elderly people to live at home for as long as ...